Pharmaceuticals

Toronto, September 7, 2022 – MORSE Consulting is delighted to announce the addition of 2 new team members, Jaclyn Beca and Sang Mi Lee who will enhance MORSE’s reimbursement expertise into pharmacoeconomics, generation and use of real world evidence (RWE) and development of innovative agreements. We are at an exciting time in drug discovery and research as new technologies, such as cell and gene therapies, offer opportunities to treat and…

Toronto, September 7, 2021 – MORSE Consulting is pleased to announce the addition of Katherine Scott as a Consultant. The Canadian public system remains one of the critical payers in this country’s pharmaceutical reimbursement pathway. This system is growing increasingly complex with new funding mechanisms for emerging gene and cell therapies, novel approaches related to outcomes-based agreements, evolving policies related to biosimilars, and variations in how provincial payers implement pCPA…

Toronto, September 9, 2020 – MORSE Consulting is pleased to announce that Sal Cimino has joined our team as Senior Consultant, Private Drug Plans. The private payer market is playing an increasingly important role in ensuring a product’s reimbursement success in Canada. With the introduction of new specialty biologics and gene therapies, private payers are turning to new cost containment strategies that strongly resemble the public payer market. Private payers…

Toronto, February 18, 2020 – MORSE Consulting is pleased to expand and strengthen our service offering with the addition of Anita Carrie and Roy Cairns. Affordability of effective and innovative medications within the current Canadian public funding model is becoming very challenging for the healthcare system.  Increasing budgetary constraints coupled with complex treatments requiring consideration of different sources and levels of evidence are an issue for all stakeholders. To help…